课题基金 / 基金详情

Transcriptomic and Genetic Endotyping of Exacerbation-Prone Asthmatics

Transcriptomic and Genetic Endotyping of Exacerbation-Prone Asthmatics
易加重哮喘的转录组学和基因内型分析
批准号:
10246165
负责人:
Max A Seibold
金额:
$42.29万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-01 至 2024-08-31

项目摘要

项目成果

Max A Seibold的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要/摘要 上呼吸道人鼻病毒(HRV)感染是引起人类感染的最大环境危险因素之一。 儿童哮喘恶化。然而,并不是所有的儿童都经历了急性加重 HRV感染。事实上,哮喘患者分为易加重和不耐加重两类。 病人。患者对病毒感染的细胞反应的变异性可以解释病情恶化的风险 在儿童哮喘患者中观察到分层。鼻呼吸道上皮是HRV感染的主要部位。 和复制,表明鼻上皮对HRV反应的重要性。我们假设 哮喘的呼吸道病理生物学机制(内型)存在异质性,其中一些可能 容易恶化。支持这一点的是,我们发现鼻部标志IL-13的高水平基因表达 在2型高哮喘内型中,与恶化风险相关。呼吸道对病毒的反应 上皮细胞可能是由呼吸道上皮的分子状态驱动的。均为内源性免疫(IL-13) 和吸入环境暴露(环境烟草烟雾(ETS))可以极大地改变 呼吸道上皮细胞的转录组图谱。此外,最近的研究发现,基因变异 影响呼吸道基因表达易导致儿童哮喘加重。因此,我们假设 免疫和/或环境“启动”的呼吸道上皮以失调的方式对病毒作出反应 感染,导致遗传易感受试者哮喘加重。为了测试这些 假设我们提出了以下目标:目标1:确定2型细胞因子是否高及其他鼻腔 表达内型与易加重哮喘相关,并预测哮喘的发生 病情加重。我们将对儿童鼻道刷牙进行全转录组测序。 哮喘易加重者(n=100)、不易加重者(n=100)和健康对照组受试者 100例。我们将确定与恶化相关的基因、途径和表达内型- 易患哮喘。目的2:确定IL-13和ETS刺激对鼻黏膜转录组反应的影响 上皮细胞(NECS)对HRV感染的反应以及这些反应是否因易加重的哮喘状态而异。空气- 来自AIM 1捐赠者的液体界面NEC培养将用模拟刺激、IL-13、ETS、HRV-A、-C或 用IL-13或ETS预置,然后感染HRV-A或-C。生成的WTS基因表达数据 这些培养物将被用于通过治疗来识别差异表达的基因。治疗反应将 在协同/拮抗分析中进行分析,以确定受IL-13干扰的HRV感染反应 或ETS前处理。目的3:我们将在体内确定呼吸道上皮细胞表达的数量性状基因座(EQTL) 易加重哮喘基因的变异。我们将确定相互作用的基因变异 免疫/环境刺激的呼吸道上皮细胞驱动对HRV感染的有害上皮反应 (响应eQTL)。我们将确定eQTL/reQTL变异,这些变异会增加易加重哮喘的风险。
英文摘要
PROJECT SUMMARY/ABSTRACT Human rhinovirus (HRV) infection of the upper airways is one of the strongest environmental risk factors for childhood asthma exacerbations. However, not all children experience an acute exacerbation in response to HRV infection. In fact, the asthmatic population is stratified into exacerbation-prone and exacerbation-resistant patients. Variability in patient cellular responses to virus infection could explain the exacerbation risk stratification observed in childhood asthmatics. The nasal airway epithelium is the primary site of HRV infection and replication, suggesting the importance of nasal epithelial responses to HRV. We hypothesize that heterogeneity exists in asthmatic airway pathobiological mechanisms (endotypes), some of which may predispose to exacerbations. Supporting this we find that high nasal gene expression levels of IL-13, a marker of the type 2-high asthma endotype, are associated with exacerbation risk. The response to virus of the airway epithelium is likely driven by the molecular state of the airway epithelium. Both endogenous immune (IL-13) and inhaled environmental exposures (environmental tobacco smoke (ETS)) can greatly alter the transcriptome profile of the airway epithelium. Additionally, recent studies have found genetic variants that affect airway gene expression predispose to childhood asthma exacerbations. Therefore, we hypothesize that an immune and/or environmentally “primed” airway epithelium responds in a dysregulated way to viral infections, resulting in asthma exacerbations among genetically predisposed subjects. To test these hypotheses we propose the following aims: Aim 1: Determine if type 2 cytokine high and other nasal expression endotypes are associated with exacerbation-prone asthma and predict occurrence of asthma exacerbations. We will perform whole transcriptome sequencing (WTS) of nasal airway brushings from children with asthma that are exacerbation-prone (n=100), exacerbation-resistant (n=100), and healthy control subjects (n=100). We will identify genes, pathways, and expression endotypes that are associated with exacerbation- prone asthma. Aim 2: Determine how IL-13 and ETS stimuli modify the transcriptome response of nasal epithelial cells (NECs) to HRV infection and if these responses vary by exacerbation-prone asthma status. Air- liquid interface NEC cultures from Aim 1 donors will be treated with mock-stimulus, IL-13, ETS, HRV-A,-C or primed with IL-13 or ETS and then infected with HRV-A or -C. WTS gene expression data generated from these cultures will be used to identify differentially expressed genes by treatment. The treatment responses will be analyzed in a synergy/antagonism analysis to identify HRV infection responses that are perturbed by IL-13 or ETS pretreatment. Aim 3: We will identify in vivo airway epithelium expression quantitative trait loci (eQTL) variants in exacerbation-prone asthma genes. We will determine genetic variants that interact with immune/environmental stimulated airway epithelium to drive deleterious epithelial responses to HRV infection (response eQTLs). We will determine eQTL/reQTL variants that confer risk of exacerbation-prone asthma.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Transcriptomic and Genetic Endotyping of Exacerbation-Prone Asthmatics
  • 批准号:
    9359963
  • 项目类别:
  • 资助金额:
    $42.95万
  • 财政年份:
    2017
  • 负责人:
    Max A Seibold
  • 依托单位:
Administrative Core
  • 批准号:
    10009470
  • 项目类别:
  • 资助金额:
    $8.08万
  • 财政年份:
    2017
  • 负责人:
    Max A Seibold
  • 依托单位:
Defining Molecular Phenotypes of Exacerbation Prone Asthmatics
  • 批准号:
    10009452
  • 项目类别:
  • 资助金额:
    $178.67万
  • 财政年份:
    2017
  • 负责人:
    Max A Seibold
  • 依托单位:
Defining Molecular Phenotypes of Exacerbation Prone Asthmatics
  • 批准号:
    10246163
  • 项目类别:
  • 资助金额:
    $178.26万
  • 财政年份:
    2017
  • 负责人:
    Max A Seibold
  • 依托单位:
海外基金